Feasability and safety of transfer from racemic methadone to (R)-methadone in primary care: Clinical results from an open study

No abstract is available for this paper.

• Publication year

  2009

• Venue

  World Journal of Biological Psychiatry

• Publication date

  2009-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/15622970802416057PMID 19629858
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Meta-Analysis

  2009cited by this paper
• World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Substance Use and Related Disorders, Part 1: Alcoholism

  2008cited by this paper
• Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.

  2008influential reference
• Feasibility and outcome of substitution treatment of heroin-dependent patients in specialized substitution centers and primary care facilities in Germany: a naturalistic study in 2694 patients.

  2008cited by this paper
• Mortality Amongst Illicit Drug Users. Epidemiology, Causes and Intervention

  2007cited by this paper
• Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation.

  2007influential reference
• Enantiomeric Metabolic Interactions and Stereoselective Human Methadone Metabolism

  2007cited by this paper
• Opioid maintenance: a comparative review of pharmacological strategies

  2007cited by this paper
• Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors.

  2006cited by this paper
• [Insufficient involvement of psychiatrists in substitution treatment].

  2006cited by this paper
• Substitutionsbehandlung Drogenabhängiger

  2006cited by this paper
• Mortality amongst Illicit Drug Users: Contents

  2006cited by this paper
• ABCB1 and cytochrome P450 genotypes and phenotypes: Influence on methadone plasma levels and response to treatment

  2006cited by this paper
• One-year Mortality Rates of Patients Receiving Methadone and Buprenorphine Maintenance Therapy: A Nationally Representative Cohort Study in 2694 Patients

  2006cited by this paper
• Die unzureichende Beteiligung von Psychiatern an der Substitutionsbehandlung

  2006cited by this paper
• Methadone-induced long QT syndrome vs methadone-induced torsades de pointes.

  2006cited by this paper
• Long-term outcome of chronic drug use: the Amsterdam Cohort Study among Drug Users.

  2005cited by this paper
• Decreasing international HIV transmission: the role of expanding access to opioid agonist therapies for injection drug users.

  2005cited by this paper
• The effects of racemic D,L-methadone and L-methadone in substituted patients--a randomized controlled study.

  2005cited by this paper
• Deaths of clients in methadone treatment in Texas: 1994-2002.

  2005cited by this paper
• Induction of patients with moderately severe methadone dependence onto buprenorphine

  2005cited by this paper
• Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence.

  2004influential reference
• Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients.

  2004cited by this paper
• Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone

  2004cited by this paper
• Subjective and physiological responses among racemic-methadone maintenance patients in relation to relative (S)- vs. (R)-methadone exposure.

  2004cited by this paper
• Transferring methadone-maintained outpatients to the buprenorphine sublingual tablet: a preliminary study.

  2003cited by this paper
• Cessation of methadone maintenance treatment using buprenorphine: transfer from methadone to buprenorphine and subsequent buprenorphine reductions.

  2003cited by this paper
• Interindividual Variability of the Clinical Pharmacokinetics of Methadone

  2002influential reference
• Pharmacokinetics and pharmacodynamics of methadone enantiomers after a single oral dose of racemate

  2001cited by this paper
• A 33-year follow-up of narcotics addicts.

  2001cited by this paper
• The impact of harm-reduction-based methadone treatment on mortality among heroin users.

  2001cited by this paper
• A meta-analysis comparing the effectiveness of buprenorphine and methadone.

  2000cited by this paper
• Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients.

  2000cited by this paper
• World Drug Report 2000

  2000cited by this paper
• The quantification of mortality resulting from the regular use of illicit opiates.

  1999cited by this paper
• L-Methadone and D,L-Methadonein Methadone Maintenance Treatment: A Comparison of Therapeutic Effectiveness and Plasma Concentrations

  1998cited by this paper
• Replacement of (R)-methadone by a double dose of (R, S)-methadone in addicts: interindividual variability of the (R)/(S) ratios and evidence of adaptive changes in methadone pharmacokinetics

  1996cited by this paper
• The Efficacy of L-methadone and Racemic Methadone in Substitution Treatment for Opiate Addicts - A Double-blind Comparison

  1996cited by this paper
• Methadone maintenance and addicts' risk of fatal heroin overdose.

  1996cited by this paper
• Stereoselective pharmacokinetics of methadone in chronic pain patients.

  1993cited by this paper
• Designing evaluations of educational and social programs

  1983cited by this paper
• Quantitation of methadone enantiomers in humans using stable isotope-labeled [2H3]-, [2H5]-, and [2H8]Methadone.

  1982cited by this paper
• Stereoselective disposition of methadone in man.

  1979cited by this paper
• Muscarinic modulation of acetylcholine release evoked by dimethylphenylpiperazinium and high potassium from guinea-pig myenteric plexus.

  1978cited by this paper
• Side effects of levomethadone and racemic methadone in a maintenance program

  1976cited by this paper

• The novel uncompetitive NMDA receptor antagonist esmethadone (REL-1017) has no meaningful abuse potential in recreational drug users

  2023cites this paper
• Esmethadone-HCl (REL-1017): a promising rapid antidepressant

  2023cites this paper
• Comment on “Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status“

  2022cites this paper
• REL-1017 (esmethadone; d-methadone) does not cause reinforcing effect, physical dependence and withdrawal signs in Sprague Dawley rats

  2022cites this paper
• REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind Trial.

  2021cites this paper
• Prevalence of Heavy Alcohol Use Among People Receiving Methadone Following Change to Methadose

  2018cites this paper
• Elevated methylation and decreased serum concentrations of BDNF in patients in levomethadone compared to diamorphine maintenance treatment

  2017cites this paper
• Patient perspectives of methadone formulation change in British Columbia, Canada: outcomes of a provincial survey

  2016cites this paper
• Sexuelle Funktionsstörungen bei Substitution mit Methadon und Levomethadon

  2016cites this paper
• Recent Advances in Drug Development

  2015cites this paper
• Relative bioavailability of a newly developed 5-mg levomethadone hydrochloride IR tablet (L-Polamidon® 5 mg tablets) in comparison with the 5-mg levomethadone hydrochloride oral solution (L-Polamidon® solution for substitution) as reference product.

  2015cites this paper
• Methadone at tapered doses for the management of opioid withdrawal.

  2013cites this paper
• Levomethadon in der Substitutionstherapie von opioidabhängigen Patienten Levamethadone as substitution treatment of opioid-dependent patients

  2013cites this paper
• Methadon und Levomethadon – Dosierung und Nebenwirkungen

  2013cites this paper
• Levomethadon in der Substitutionstherapie von opioidabhängigen Patienten

  2013cites this paper
• Is it Time to Consider Use of Levo-methadone (R-(-)-Methadone) to Replace Racemic Methadone?

  2013cites this paper
• Pharmacological treatments of opiate dependence.

  2011cites this paper
• The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Substance Use and Related Disorders. Part 2: Opioid dependence

  2011cites this paper
• Current World Literature

  2010cites this paper